. Author manuscript; available in PMC: 2020 Mar 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2018 Oct 18;25(3):577–586. doi: 10.1016/j.bbmt.2018.10.011

Table 2.

Kaplan-Meier survival curve point estimates.

	1 year Overall Survival	p-value	Day +100 CMV-free survival	p-value	Day +100 CMV-free, steroid-free, GF-free survival	p-value
D/R Serostatus		NS		<0.0001		<0.0001
−/−	86% (77–92%)		93% (85–97%)		51% (40–61%)
−/+	76% (64–85%)		39% (28–51%)		27% (17–38%)
+/−	84% (65–93%)		84% (66–93%)		55% (36–70%)
+/+	78% (71–84%)		41% (33–49%)		25% (19–32%)
Graft Source		NS		0.01		0.08
Marrow	83% (72–90%)		55% (42–66%)		35% (24–46%)
PBSC	79% (74–84%)		62% (56–67%)		37% (31–43%)
UCB	84% (63–94%)		40% (21–58%)		20% (7–37%)
T-cell Manipulation		NS		0.08		NS
PTCy-based	84% (72–91%)		57% (43–69%)		39% (27–52%)
Serotherapy	91% (83–96%)		67% (56–76%)		41% (31–52%)
TCD	87% (73–94%)		60% (44–73%)		29% (17–42%)
CNI/mTORi-based	78% (70–84%)		58% (44–65%)		35% (28–43%)

Abbreviations: CMV, cytomegalovirus; GF, graft failure; D/R, donor/recipient; PBSC, peripheral blood stem cell; UCB, umbilical cord blood; PTCy, post-transplantation cyclophosphamide; TCD, ex vivo T-cell depletion; CNI, calcineurin inhibitor; mTORi, mammalian target of rapamycin inhibitor